Connect with us

BUSINESS

Lexaria Bioscience Corp (OTCMKTS:LXRP) Announces Advancement In Testing Of Edibles Nicotine; Bioavailability Results

Published

on

Lexaria Bioscience Corp (OTCMKTS:LXRP) recently announced that the company has been successful at delivering edible nicotine into blood plasma. The nicotine was delivered in vivo study a few minutes after dosing. As per the report, DehydraTECH technology developed by Lexaria delivered the edible nicotine at regular intervals of 2,4,6,8 and 10-minute after dosing in the animal. The study showed greater absorption levels as compared to control formulation.

Key highlights of study

Speed is of significant importance for oral drug administration. Importantly, its contribution is profound in the non-inhalation nicotine delivery format. During its third-party laboratory test, the study primarily kept its focus on analyzing absorption of edible nicotine over a period of 60 minutes giving particular emphasis on the dosing after first 15 minutes. This particular study was a follow-up of the vivo study conducted by Lexaria conducted on April 17 this year. In this study, the company tried the absorption level in smaller animal population in the time span of six hours.

The study revealed 79% improvement in blood levels at their peak at 394 ng/mL when DehydraTECH technology of Lexaria was compared against 220 ng.mL dose with control.

Lexaria’s bioavailability results

Recently the company revealed its bioavailability results from its placebo-controlled, randomized, double-blind European clinical study. In this study, DehydraTECH powered proprietary TurboCBD fortified with cannabidiol (CBD) hemp oil capsule was evaluated. The study detected the speed and degree in which the blood absorbed CBD into the blood plasma. Simultaneously, the study also tracked down whether the capsule potentially enhanced cognitive and cardiovascular performance in 12 male volunteers in their prime health.

It should be noted that very few companies have managed to achieve this success in a placebo-controlled, randomized, and double-blinded, appropriately controlled clinical trial in human volunteers. Such evaluations are highly important as they can be used as clinical evidence during the regulatory CBD scrutiny carried out by the US Food and Drug Administration in future. Also, the study will help in improving the commercial viability of Lexaria’s product containing CBD. Lexaria’s DehydraTECH technology has been repeatedly successful in producing evidence during human studies. That is why the company will hopefully continue to use this technology for other trials in human studies in the future.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

VIVO Cannabis Inc (OTCMKTS:VVCIF) Subsidiary Beacon Medical Australia Pty Signs a Supply Agreement Deal With MediPharm Labs Australia Pty. Ltd.

Published

on

The use of cannabis among adolescents and young adults is very common in the US., daily increase of its use has birthed new industry players and partnerships. The newest partnership in the market is that of Beacon Medical Australia Pty. Ltd with MediPharm Labs Australia Pty. Ltd.

The former is a subsidiary of VIVO Cannabis Inc (OTCMKTS:VVCIF) a key player in the market, and presents premium products and services. In their one-year term supply agreement, Beacon Medical will supply branded medical cannabis products. The duo will work together to keep the emerging markets fully supplied with the GMP-certified, formulated CBD and THC cannabis oil products.

The Urge to Pursue the Emerging Australian and German Markets

The Therapeutic Goods Administration (TGA) says that the medical cannabis market in Australia is among those that are growing very fast today. The customer needs for medical-grade products within the Australian domestic Markets are burgeoning by the day.

VIVO’s focus is on the international markets, according to the company’s CEO Barry Fishman. On the other hand, MediPharm Labs, Asia Pacific, CEO Warren Everitt says they are optimistic about the rapid success of being able to convert all the present opportunities into a tangible, revenue-generating business.

“We have a very clear roadmap for international expansion and now the means to begin achieving our objectives in a risk-managed but assertive fashion,” noted Pat McCutcheon, CEO, MediPharm Labs.

Expansion of Distribution Network and Production Capabilities by Vivo Cannabis

Over the years, VIVO has been scaling the heights while targeting different segments. The corporation, which has strong production and sales licenses, operates world-class cultivation facilities. To date, the company has had more than 100,000 patient visits through its telemedicine platform and the Harvest Medicine clinics. As if this is not enough, there are several other partnerships awaiting completion and conclusion.

Canna Farms Limited, the company’s wholly-owned subsidiary, is about to embark on its operations within the Phase 5 expansion. According to President of Canna Farms, Dan Laflamme, this houses 10,000 square feet of production space and is a major milestone. Through the new phase, the company will be able to grow twice as many plants, thus being able to meet the increasing demand for craft quality cannabis.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Souvenir Branded High-Quality Cannabis from Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) Now In Québec

Published

on

The cultivation and sale of cannabis are still one of the many booming activities in Canada after the legalization of recreational marijuana in October 2018. In Quebec, the permitted age for buying and possessing cannabis is 21years. This is perhaps what has driven Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) to establish a base in Emerald Health Therapeutics, Inc.

Through its subsidiary, Verdélite Sciences has unveiled a new Souvenir Cannabis brand primarily for adult recreational marijuana users. The Souvenir comes in blue and white packaging with Fleur-de-lys and will bring a new experience to the Quebec market.

The Souvenir product line has over 80 years of cannabis growing experience in Québec

‘’The team at Verdélite has poured heart and soul into this launch, perfecting growing methods and bringing the brand concept to life. We look forward to continuing our relationship with the SQDC and providing Québec with great cannabis,” says VP General Manager of Verdélite, Maheep Dhillon.

Verdélite’s commitment has been displayed through the unmistakable quality of the Souvenir craft batches. Every batch of dried flower comes with a competitive price point. The distribution will be done through the Société Québécoise du Cannabis (SQDC) online stores as well as the retail stores. With this determination, SQDC’s 42 operational stores are likely to scale up to 70 stores by the end of the year.

Consumers within the Québec market will first have Chemdog and Grapefruit GG4, being the initial products the company will be launching.

The two, which have high potency THC strains, different aromas, and flavors, will be sold in 3.5g packages plans to introduce other formats and categories underway.

Cutbacks on Canada’s recreational market

Over the years, the Canadian recreational market has been doing so well. However, the legal market is no longer able to attract serious buyers, thanks to the black market, which has remained a strong preference for hundreds of people. They claim the legal product is more expensive and that the government does not reveal what one is buying before.

This has caused major issues to North America’s marijuana companies, which are now at a limbo of whether or not they should open more stores. In addition to this, companies also have to endure strict advertising rules.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Zenabis Global Inc (OTCMKTS:ZBISF) Extends $7 Million Debt; Has 111,200 Kg Of Products For Leading Facilities

Published

on

Zenabis Global Inc (OTCMKTS:ZBISF) spoke about its “best efforts” offering. Unveiled today, the units are part of its grand scheme to thrive in a dynamic business climate.

A close outlook

A lot has been happening; lately, part of that being the striking of a series of agreements with lenders. The company hopes to succeed in its plan to advocate the extension of the due date that it was supposed to pay a debt amounting to $7M. This forms part of the larger debt that had been borrowed in December. It was a figure totaling up to $61M.

Zenabis Global has, over the years, stood out among the rest as one of the best performing and licensed cultivators of recreational and medical marijuana. Asides from this, the business guru has also been focusing on the cultivation of vegetable and floral products.

Plans into the future

To reach its business goals, the company intends to channel some of its funds to employing some new staff members. It will be taking staff members from facilities situated in Atholville, Aldergrove, Langley, and Pitt Meadows.

The company has so far made significant strides forward in terms of business achievements. For instance, it already has about 111,200 kg of its top-notch products only for its leading facilities. It continues to express great determination in line with the production of some top quality licensed cannabis products.

With its cultivation space that adds up to 3.5 million square feet, the business giant hopes to employ the best cultivation practices that will help it rise to become a market leader in a diverse and fast-changing business climate.

Major business moves

If all moves according to plan, the business expresses optimism that it will succeed on its quest to link its Zenabis Langley and Zenabis Stellarton to its Zenabis Atholvlle. This is a move deemed to play a huge role in helping it uphold a steady production in years to come.

The Zenabis brand name is usually applied within the cannabis market. On the other hand, there are terms used for the cannabis adult-use market recreational segment. These names include Blazery, Namaste, and Re-Up.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories